Barclays Maintains Equal-Weight on Moderna, Raises Price Target to $48

Barclays analyst Eliana Merle has maintained an Equal-Weight rating on Moderna (NASDAQ: MRNA) while increasing the price target from $25 to $48. This adjustment reflects a positive outlook on the company's performance.